A Phase 2 interventional study of Bilastine and Placebo in Seasonal Allergic Rhinitis, Hay Fever and Rhinoconjunctivitis, sponsored by Faes Farma, S.A.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Faes Farma, S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada — 2 open to participants now, 3 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Canada.
Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, this one is the 2nd largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2007, is one of 18 in phase 2, and was the 7th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →2 of the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada are open now. Recruiting first, the newest first:
Dr. Anne Ellis · Sites in Canada
Ages 18–70 · Healthy volunteers
Alixer Nexgen Therapeutics Limited · Sites in Canada
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 502 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 104 across the 32 interventional studies, 12 across the 1 observational. Of the 30 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 33 have an industry lead sponsor. The 10 most frequent:
Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Faes Farma, S.A. has 7 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic, Seasonal with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06189742Dr. Anne EllisTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the relative efficacy of four dosing regimens of bilastine tablets versus placebo in subjects with SAR exposed in controlled ragweed pollen using the EEC model based on the mean change from baseline in Total Nasal Symptom Scores (TNSS). Study includes male and female subjects, aged 18 and 65 years with clinical history of SAR with seasonal onset and offset of nasal allergy symptoms during each of the last two ragweed allergy seasons and a positive skin prick test to ragweed allergen within 12 months prior to randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
Drug: Bilastine
Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
Drug: Bilastine
Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
Drug: Bilastine
Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
Drug: Bilastine
Placebo oral twice per day (2 placebo tablets)
Drug: Placebo
Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
Placebo Tablets administered twice per day
Total Nasal Symptom Scores (TNSS)
Time frame: within 10 days
Total Symptom Scores (TSS), Total Non-Nasal Symptom Scores (TNNSS), Total Ocular Symptoms Scores (TOSS), Area Under the Curve (AUC) of TNSS, TSS, TOSS, TNNSS, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ - EEC)
Time frame: witin 10 days
The record gives a start of Oct 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bilastine
Rhinitis, Allergic, Seasonal →
Faes Farma, S.A.